File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Reverse cholesterol transport in type 2 diabetes mellitus

TitleReverse cholesterol transport in type 2 diabetes mellitus
Authors
Issue Date2009
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/DOM
Citation
Diabetes, Obesity And Metabolism, 2009, v. 11 n. 6, p. 534-543 How to Cite?
AbstractHigh-density lipoprotein (HDL) plays an important protective role against atherosclerosis, and the anti-atherogenic properties of HDL include the promotion of cellular cholesterol efflux and reverse cholesterol transport (RCT), as well as antioxidant, anti-inflammatory and anticoagulant effects. RCT is a complex pathway, which transports cholesterol from peripheral cells and tissues to the liver for its metabolism and biliary excretion. The major steps in the RCT pathway include the efflux of free cholesterol mediated by cholesterol transporters from cells to the main extracellular acceptor HDL, the conversion of free cholesterol to cholesteryl esters and the subsequent removal of cholesteryl ester in HDL by the liver. The efficiency of RCT is influenced by the mobilization of cellular lipids for efflux and the intravascular remodelling and kinetics of HDL metabolism. Despite the increased cardiovascular risk in people with type 2 diabetes, current knowledge on RCT in diabetes is limited. In this article, abnormalities in RCT in type 2 diabetes mellitus and therapeutic strategies targeting HDL and RCT will be reviewed. © 2009 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/163244
ISSN
2015 Impact Factor: 6.198
2015 SCImago Journal Rankings: 2.729
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTan, KCBen_US
dc.date.accessioned2012-09-05T05:29:06Z-
dc.date.available2012-09-05T05:29:06Z-
dc.date.issued2009en_US
dc.identifier.citationDiabetes, Obesity And Metabolism, 2009, v. 11 n. 6, p. 534-543en_US
dc.identifier.issn1462-8902en_US
dc.identifier.urihttp://hdl.handle.net/10722/163244-
dc.description.abstractHigh-density lipoprotein (HDL) plays an important protective role against atherosclerosis, and the anti-atherogenic properties of HDL include the promotion of cellular cholesterol efflux and reverse cholesterol transport (RCT), as well as antioxidant, anti-inflammatory and anticoagulant effects. RCT is a complex pathway, which transports cholesterol from peripheral cells and tissues to the liver for its metabolism and biliary excretion. The major steps in the RCT pathway include the efflux of free cholesterol mediated by cholesterol transporters from cells to the main extracellular acceptor HDL, the conversion of free cholesterol to cholesteryl esters and the subsequent removal of cholesteryl ester in HDL by the liver. The efficiency of RCT is influenced by the mobilization of cellular lipids for efflux and the intravascular remodelling and kinetics of HDL metabolism. Despite the increased cardiovascular risk in people with type 2 diabetes, current knowledge on RCT in diabetes is limited. In this article, abnormalities in RCT in type 2 diabetes mellitus and therapeutic strategies targeting HDL and RCT will be reviewed. © 2009 Blackwell Publishing Ltd.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/DOMen_US
dc.relation.ispartofDiabetes, Obesity and Metabolismen_US
dc.subject.meshAtp-Binding Cassette Transporters - Metabolismen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAnticholesteremic Agents - Pharmacologyen_US
dc.subject.meshApolipoprotein A-I - Pharmacologyen_US
dc.subject.meshBiological Transporten_US
dc.subject.meshCholesterol Ester Transfer Proteins - Antagonists & Inhibitorsen_US
dc.subject.meshCholesterol Esters - Metabolismen_US
dc.subject.meshDiabetes Mellitus, Type 2 - Metabolismen_US
dc.subject.meshHumansen_US
dc.subject.meshHydroxymethylglutaryl-Coa Reductase Inhibitors - Pharmacologyen_US
dc.subject.meshHypolipidemic Agents - Pharmacologyen_US
dc.subject.meshLipoproteins, Hdl - Drug Effects - Metabolismen_US
dc.subject.meshLiver - Metabolismen_US
dc.subject.meshMiceen_US
dc.subject.meshNiacin - Pharmacologyen_US
dc.subject.meshOrphan Nuclear Receptors - Agonistsen_US
dc.subject.meshPeroxisome Proliferator-Activated Receptors - Agonistsen_US
dc.subject.meshQuinolinesen_US
dc.subject.meshRabbitsen_US
dc.subject.meshScavenger Receptors, Class B - Metabolismen_US
dc.subject.meshThiazolidinediones - Pharmacologyen_US
dc.titleReverse cholesterol transport in type 2 diabetes mellitusen_US
dc.typeArticleen_US
dc.identifier.emailTan, KCB:kcbtan@hku.hken_US
dc.identifier.authorityTan, KCB=rp00402en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1463-1326.2008.01012.xen_US
dc.identifier.pmid19175378-
dc.identifier.scopuseid_2-s2.0-65549094721en_US
dc.identifier.hkuros158351-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-65549094721&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume11en_US
dc.identifier.issue6en_US
dc.identifier.spage534en_US
dc.identifier.epage543en_US
dc.identifier.isiWOS:000265884200002-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTan, KCB=8082703100en_US
dc.identifier.citeulike4500862-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats